Location of Trial:
Washington University School of Medicine
John L. Trotter MS Center
Name of Trial:
Prevent
Description:
The purpose of this study is to determine if eculizumab is safe and effective for preventing relapses in patients with relapsing NMO (Neuromyelitis Optica).
Participant Criteria: (age, type of MS (if necessary):
1. Age: > 18 years old
2. Diagnosis of NMO or NMOSD
3. EDSS < 7 (Unable to walk approximately five meters even with aid, essentially restricted to wheelchair)
4. For female participants, no desire for pregnancy during the study.
Length of Trial:
3 – 4 years
Clinical Trial Sponsor:
Alexion Pharmaceuticals, Inc.
Contact: (Name, phone #, email):
Susan Fox, Research Patient Coordinator
314-362-2017
Neurology, Campus Box 8111
660 South Euclid Ave.